YZYBIO

YZY Biopharma is a clinical-stage biotechnology company headquartered in Wuhan, China, specializing in the development of bispecific antibody (BsAb) therapies. The company leverages its proprietary technology platforms, including YBODY®, Check-BODY, and Nano-YBODY, to design innovative biologics for oncology and ophthalmology. Its lead candidate, M701, is a bispecific antibody targeting EpCAM and CD3, currently in Phase 3 clinical trials for the treatment of malignant ascites. Other key programs include M802 for HER2-positive cancers and Y101D, a PD-L1/TGF-beta bifunctional fusion protein. YZY Biopharma is listed on the Hong Kong Stock Exchange and maintains integrated capabilities spanning drug discovery, clinical development, and GMP-compliant manufacturing.